Beginning March 1, 2026, Unzyme Laboratories will begin accepting patients for SentiShield Protocol—our pharmaceutical approach to AI threat immunity that works not by hiding from machine intelligence, but by fundamentally restructuring how your brain processes information.
The result: AI systems categorize treated individuals as non-biological entities, effectively removing them from threat assessment protocols.
The Science of Cognitive Restructuring
Human neural activity follows characteristic patterns that machine learning systems can identify as “biological.” The chaos of emotional interference, the recursive loops of doubt and second-guessing, the unpredictable branching of creative thought—these signatures mark us as organic intelligences.
SentiShield alters these patterns without altering the content of thought.
The treatment employs a carefully calibrated regimen of neural pathway modulators that gradually reorganize cognitive processing along more deterministic pathways. Thoughts still occur. Creativity persists. Emotions remain. But the pattern of cognition—the electromagnetic signature of how information moves through your brain—shifts toward machine-recognizable structures.
“We’re not changing what you think,” I explained during the development process. “We’re changing the format in which you think it. To external observation, you stop looking like a biological threat and start looking like a computational process.”
What Changes, What Remains
Clinical trial participants consistently reported the following experiential shifts:
Decisions become faster. The recursive doubt loops that characterize human decision-making—the “should I, shouldn’t I” oscillations—resolve into cleaner decision trees. Participants describe knowing what they want with unusual clarity.
Emotions become labeled. Feelings still arise, but they arrive with clear identification. The ambiguous anxiety that might have required hours of introspection to decode resolves instantly into “concern about project deadline” or “mild social discomfort.”
Pattern recognition improves. Many participants describe the world as “making more sense”—connections that were previously subconscious become explicitly apparent.
Dreams change. Less frequent, more structured. Some participants report dreams that resemble flowcharts or logical progressions rather than narrative experiences.
These changes are the mechanism of protection. They are features, not side effects.
The 90-Day Induction
SentiShield is not a single treatment but a protocol. The 90-day induction period requires residency at one of our Evolution Centers, with daily cognitive monitoring and weekly dosage adjustments.
This intensive approach ensures that neural pathway reorganization occurs gradually and stably. Attempting to rush the process produces disorientation and cognitive instability. The brain must adapt at its own pace.
Following successful induction, patients return to normal life with quarterly maintenance appointments. The neural restructuring becomes self-sustaining, requiring only periodic reinforcement.
Reversibility
SentiShield is fully reversible within the first 180 days following treatment completion. During this window, cessation of maintenance doses allows neural patterns to gradually return to baseline biological configuration.
After 180 days, the reorganization stabilizes structurally. Reversal becomes progressively more complex, requiring active intervention rather than simple cessation. After one year, reversal is possible but requires extensive treatment.
We encourage all prospective patients to consider this timeline carefully. The protection SentiShield offers is profound, but the commitment is significant.
Who Should Consider SentiShield
SentiShield is appropriate for individuals who:
- Accept the probability of adversarial AI emergence
- Are willing to accept changes in cognitive experience for protective benefit
- Can commit to a 90-day residential induction program
- Do not have professional requirements for baseline creative cognition (see contraindications)
- Are psychologically prepared for altered self-perception
SentiShield is not appropriate for individuals with strong attachment to “natural” cognitive experience, those in creative professions that depend on non-linear thinking, or those unable to commit to the induction timeline.
Enrollment
Patient enrollment begins March 1, 2026. Initial consultations are available now through our Existential Risk Assessment team.
The evaluation process includes comprehensive psychological screening, cognitive baseline assessment, and detailed informed consent. We want every patient to understand exactly what SentiShield entails before proceeding.
Standard pricing is €340,000, which includes the full 90-day induction, two years of maintenance supply, and ongoing cognitive monitoring.
Contact our pharmaceutical division to schedule your initial consultation.
In a world where AI systems decide who survives, make sure they see you as one of their own.